Clinical trials: NMDAR Autoimmune Encephalitis
NMO Spectrum Disorder, NMDA-R Encephalitis
Sensitivity and Specificity of TSA-CBA for Autoantibodies Against Neural Antigen Determination
Determination of autoantibodies against fragments derived from neurons, glia, and myelin sheath is instrumental in aiding diagnosis, differential diagnosis, as well as determining disease status of neuromyelitis optica spectrum…
- Conditions
- NMO Spectrum Disorder, NMDA-R Encephalitis, Diagnostic Self Evaluation, Immune System Diseases
- Trial name
- STAND (NCT05414890)
- Testing
- CBA-TSA
- Where
- China
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Beijing Tiantan Hospital
Encephalitis Autoimmune
Efgartigimod in Anti-NMDA Receptor Encephalitis.
This study is a multicenter, open-label, single-arm exploratory trial designed to enroll 20 eligible patients with anti-NMDAR encephalitis.
- Trial name
- ANSWER (NCT07822776)
- Testing
- Efgartigimod Alfa
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Tongren Hospital
Autoimmune Encephalitis
Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism
Prospective cohort study evaluating FDG PET in 56 patients with confirmed autoimmune encephalitis - based on 2016 Graus criteria, and 2021 paraneoplastic neurological syndromes criteria - at the acute phase, before…
- Trial name
- ENCEPHATAIP (NCT06079294)
- Testing
- FDG PET
- Where
- France
- Volunteers
- 56 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Autoimmune Encephalitis
GWAS in NMDAR Encephalitis
Autoimmune encephalitis are characterized by the subacute development of memory deficits, altered mental status, and psychiatric symptoms, generally in association with anti-neuronal antibodies.
- Trial name
- NCT05225883
- Testing
- GWAS
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- Hospices Civils de Lyon
Autoimmune Encephalitis, Encephalitis
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and…
- Trial name
- ExTINGUISH (NCT04372615)
- Testing
- Inebilizumab
- Where
- 39 sites in United States, Netherlands and 1 more
- Volunteers
- 116 people
- Sponsor
- University of Utah
Optic Neuritis, Transverse Myelitis
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
The Swiss-Ped-IBrainD is a national patient registry that collects information on diagnosis, symptoms, treatment, and follow-up of pediatric patients with an inflammatory brain disease in Switzerland.
- Conditions
- Optic Neuritis, Transverse Myelitis, Acute Disseminated Encephalomyelitis, Multiple Sclerosis
- Trial name
- NCT05017142
- Where
- 13 sites in Switzerland
- Volunteers
- 500 people
- Sponsor
- University of Bern
Anti-NMDA Receptor Encephalitis
Transcranial Direct Current Stimulation on Cortical Plasticity in Patients With Anti-NMDA Receptor Encephalitis
Patients suffering from anti-NMDA receptor encephalitis show impaired NMDA-receptor dependent neuronal transmission. Furthermore, they often have cognitive deficits of different magnitude.
- Trial name
- NCT01865578
- Testing
- tDCS
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
Autoimmune Encephalitis
Long-term Impact of NMDAR Encephalitis
NMDA receptor antibody encephalitis is a rare autoimmune neurological disease of the central nervous system with an estimated incidence of 1.5 people per million per year.
- Trial name
- SAPIENCE2 (NCT06609044)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Hospices Civils de Lyon
Anti-N-Methyl-D-Aspartate Receptor Encephalitis, Autoimmune Encephalitis
Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis
Autoimmune encephalitis is brain inflammation caused by the immune system mistakenly reacting against proteins in the brain. The commonest form is called NMDAR-antibody encephalitis (N-methyl-D-aspartate receptor antibody…
- Trial name
- DANCE-AE (NCT05280600)
- Testing
- Not applicable - non-interventional study
- Where
- United Kingdom
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- King's College London
Neuropsychiatric Symptom
Dissecting Immunological and Autoimmune Mechanisms of Neuropsychiatric Diseases
The goal of this observational cohort study is to investigate the role of immune system in neuropsychiatric symptoms (NPS) and to identify immunological biomarkers that may improve the diagnosis, prognosis, and future treatment…
- Trial name
- DIAMOND (NCT07791212)
- Where
- 2 sites in United Kingdom
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- King's College London
Autoimmune Encephalitis, Anti-NMDAR Encephalitis
Clinical Evaluation of a Novel DAB Chromogenic Tissue-Based Assay for Detecting Anti-GABABR Antibodies
This multicenter, blinded, cross-sectional study aims to evaluate the clinical performance of a novel DAB chromogenic tissue-based assay (TBA) for detecting anti-GABAB receptor (anti-GABABR) antibodies.
- Conditions
- Autoimmune Encephalitis, Anti-NMDAR Encephalitis, Anti-GABABR Encephalitis
- Trial name
- GREAT (NCT07858175)
- Where
- 5 sites in China
- Volunteers
- 300 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Autoimmune Encephalitis
Phase 1 Study of ART5803 in Healthy Participants
The study is a Phase 1, single-center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, pharmacokinetics (PK), and…
- Trial name
- NCT06575153
- Testing
- ART5803
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Arialys Therapeutics
NMDAR Autoimmune Encephalitis
Long-term Impact of NMDAR Encephalitis, Level 3
NMDA receptor antibody encephalitis is a rare autoimmune neurological disease of the central nervous system with an estimated incidence of 1.5 people per million per year.
- Trial name
- SAPIENCE 3 (NCT07158229)
- Testing
- Questionnaires
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Hospices Civils de Lyon
Autoimmune Encephalitis
Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis
Autoimmune Encephalitis is a disorder of the central nervous system caused by bodily substances, called antibodies. Antibodies normally help the body to prevent infections.
- Trial name
- Generate-Boost (NCT03993262)
- Testing
- Bortezomib
- Where
- 17 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Jena University Hospital
Anti-NMDA Receptor Encephalitis
Antibody-mediated NMDA Receptor Encephalitis: Symptoms, Biomarkers, and Mechanisms of the Prolonged Recovery Stage
The encephalitis mediated by antibodies against the NMDA receptor (NMDARe) predominantly affects young adults and children resulting in severe neurologic and psychiatric deficits.
- Trial name
- AMENDS (NCT06183788)
- Testing
- Remote cognitive rehabilitation program
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis
Autoimmune encephalitis is an autoimmune disease of the central nervous system that targets neuronal autoantigens. Anti-neuronal autoantibodies are produced in patients, with anti-NMDAR antibody being the most common.Anti-NMDAR…
- Trial name
- RADIA (NCT06867991)
- Testing
- Ofatumumab combined with daratumumab, Ofatumumab, Repeated intravenous immunoglobulin/plasma exchange therapy
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- The First People's Hospital of Changzhou
Anti NMDA Receptor Encephalitis
Clinical-immunological Features of Anti-NMDAR Encephalitis
Using a retrospective cohort of 501 patients with anti-NMDAR encephalitis to assess clinical and immunological prognostic biomarkers
- Trial name
- Bio-NMDAr (NCT05738668)
- Testing
- Description of clinical characteristic
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Hospices Civils de Lyon
Autoimmune Encephalitis, Anti NMDA Receptor Encephalitis
Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis
Herpes Simplex Virus encephalitis is the most common infectious encephalitis, with an estimated annual incidence of 1 / 250,000 to 1 / 500,000 in industrialized countries.
- Conditions
- Autoimmune Encephalitis, Anti NMDA Receptor Encephalitis, Herpetic Encephalitis
- Trial name
- NMDARE-HSE (NCT04339127)
- Testing
- Description and analysis
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Hospices Civils de Lyon
Autoimmune Encephalitis, Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody (Disorder)
Validation of a Diagnostic Score for Encephalitis to Assess the Risk of Autoimmune Origin
The investigators wish to test a diagnostic risk score for autoimmune encephalitis in case of encephalitis, previously validated by two American teams, in a retrospective analysis, according to the clinical and paraclinical data…
- Trial name
- Val-Dia score (NCT05953974)
- Testing
- Clinical score of Granillo and al.
- Where
- France
- Volunteers
- 350 people
- Sponsor
- Hospices Civils de Lyon
Anti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE), Anti-N-methyl-D-aspartate Receptor (NMDAR) Antibody-associated Psychiatric Disease
A Study in Participants With Anti-NMDAR Encephalitis and Anti-NMDAR Autoantibody-Associated Psychiatric Disease
This study will evaluate the safety, tolerability, preliminary efficacy and pharmacokinetics (PK) of ART5803 in adult participants with a confirmed diagnosis of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis (ANRE) or…
- Conditions
- Anti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE), Anti-N-methyl-D-aspartate Receptor (NMDAR) Antibody-associated Psychiatric Disease, Autoimmune Encephalitis
- Trial name
- NCT07093333
- Testing
- ART5803, ART5803-Cohort D
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Arialys Australia Pty Ltd